title: The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.
abstract: MF59 is a safe and effective vaccine adjuvant that has been used in a licensed seasonal influenza vaccine for 15 years. The purpose of the present studies was to directly address a question that has been asked of us on many occasions: "which is the adjuvant active component of MF59?". Since we have recently gained a number of insights on how MF59 works as an adjuvant, we were able to use these approaches to evaluate if the individual components of MF59 (squalene oil, the surfactants Span 85 and Tween 80 or the citrate buffer) showed any direct immunostimulatory activity. We assessed the ability of the individual components to stimulate the innate and adaptive immune responses that we have shown to be indicative of MF59-mediated adjuvanticity. No immune stimulatory capacities could be attributed to squalene, Tween 80 or the citrate buffer alone. Instead, we found that the lipophilic surfactant Span 85 contributes to activation of the muscle transcriptome. However, despite this local activation, Span 85 alone - like the other single components of MF59 - is not sufficient to induce an adjuvant effect. Only the fully formulated MF59 emulsion induces all the established hallmarks of innate and adaptive immune activation, which includes activation of genes indicative of transendothelial cell migration, strong influx of immune cells into the injection site and their enhanced antigen uptake and transport to the lymph nodes. These observations may have important implications in the design of optimal emulsion-based vaccine adjuvants.
authors.affiliation: Novartis Vaccines and Diagnostics Research Center, Via Fiorentina 1, I-53100 Siena, Italy.
authors.forename: Samuele
authors.initials: S
authors.lastname: Calabro
authors.forename: Elaine
authors.initials: E
authors.lastname: Tritto
authors.forename: Annamaria
authors.initials: A
authors.lastname: Pezzotti
authors.forename: Marianna
authors.initials: M
authors.lastname: Taccone
authors.forename: Alessandro
authors.initials: A
authors.lastname: Muzzi
authors.forename: Sylvie
authors.initials: S
authors.lastname: Bertholet
authors.forename: Ennio
authors.initials: E
authors.lastname: De Gregorio
authors.forename: Derek T
authors.initials: DT
authors.lastname: O'Hagan
authors.forename: Barbara
authors.initials: B
authors.lastname: Baudner
authors.forename: Anja
authors.initials: A
authors.lastname: Seubert
mesh_terms: D056704:Adaptive Immunity; D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D017951:Antigen Presentation / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004655:Emulsions / Q000737:chemistry / Q000494:pharmacology*; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006601:Hexoses / Q000494:pharmacology; D006801:Humans; D007113:Immunity, Innate; D007252:Influenza Vaccines / Q000494:pharmacology; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009000:Monocytes / Q000276:immunology; D011136:Polysorbates / Q000737:chemistry / Q000494:pharmacology*; D013185:Squalene / Q000737:chemistry / Q000494:pharmacology*; D059467:Transcriptome / Q000187:drug effects
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D004655:Emulsions; D006601:Hexoses; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene; C005693:sorbitan trioleate
keywords: Emulsion; Mechanism of action; Vaccine adjuvant